Newly synthesized proteins that fail to fold or assemble properly in the endoplasmic reticulum are degraded. Recent work on several endoplasmic reticulum membrane proteins has shown that the cytosolic proteasome plays a role in their degradation.
Most membrane and secretory proteins, and proteins ultimately located in organelles such as the Golgi complex, endosomes or lysosomes, are synthesized on ribosomes that attach to the endoplasmic reticulum (ER) membrane during translation. During their synthesis, these proteins are either inserted into the ER membrane in the correct orientation or discharged into the ER lumen before moving to their final location within or outside the cell. But the ER is much more than simply the site of synthesis of these proteins; its lumen provides an environment in which the nascent proteins fold, undergo a variety of post-translational modifications and, when appropriate, assemble into oligomeric structures. This is generally described as the 'quality control' function of the ER [1] . To do this efficiently and effectively, the ER lumen has a repertoire of proteins that includes molecular chaperones and folding and modifying enzymes. Only when a protein is correctly folded and assembled can it exit the ER for another destination.
What happens to proteins that fail to fold correctly, or fail to assemble into oligomeric complexes within the ER? They do not simply accumulate and remain in this compartment. Rather, they are selectively degraded by a proteolytic system able to differentiate between native and aberrant conformations [2] . The plasma membrane T-cell receptor complex provides a good example. It is an oligomer of at least seven different polypeptides that are synthesized in different amounts in the ER. The number of correctly assembled heptameric T-cell receptor complexes formed is limited by the availability of the least abundant constituent, and only heptameric T-cell receptor complexes are correctly targeted to the cell surface; partial T-cell receptor complexes and individual subunits are rapidly destroyed.
When the ␣ subunit of the T-cell receptor is expressed alone in transfected fibroblasts, it is core glycosylated and undergoes normal glycan trimming by ER processing enzymes, but the oligosaccharide side chain remains sensitive to endo H digestion; the glycoprotein never acquires the resistance to endo H that is diagnostic of transport to and modification within the Golgi complex. Furthermore, the subsequent proteolytic removal of the ␣ subunit is insensitive to drugs that inhibit proteolysis in lysosomes. Thus, degradation most likely occurs in a pre-Golgi compartment, possibly the ER lumen itself [3] . In addition to T-cell receptor subunits, several other ER membrane proteins are substrates for degradation, including HMG-CoA reductase, ribophorin, the asialoglycoprotein receptor and apolipoprotein B-100 [4] .
These observations suggest the slightly uncomfortable notion that the protein folding and quality control machinery co-exist in the ER lumen with a proteolytic system capable of rapidly degrading newly synthesized proteins. Recent findings, however, are beginning to challenge the idea that protein degradation occurs exclusively within the ER. That incorrectly folded or unassembled proteins unable to exit the ER by vesicular transport are rapidly degraded is not in dispute, it is the site of degradation that is now being questioned.
The cystic fibrosis transmembrane conductance regulator (CFTR) is another integral membrane protein subjected to extensive post-translational degradation. Approximately 75 % of wild-type CFTR and 100 % of the ⌬F508 CFTR variant found in most cystic fibrosis patients does not mature beyond the ER and is degraded. Last year, it was demonstrated that degradation of both wild-type and mutant CFTR is prevented by inhibitors of the cytosolic proteasome, and that ubiquitination is required for rapid degradation [5, 6] . Another recent paper [7] has shown that, in yeast, the ubiquitin-proteasome pathway is involved in the degradation of Sec61p, an essential component of the translocon that delivers nascent proteins into the ER.
Are cytosolic proteasomes entirely responsible for degrading these proteins, or are they an important constituent of a more complex proteolytic system? The orientation of CFTR in the ER membrane is such that the bulk of the protein is exposed to the cytosol and might therefore be available for proteasome processing without any alteration in membrane topology. For other membrane proteins, such as Sec61p, it is conceivable that the ubiquitin-proteasome pathway initiates degradation and is responsible for degrading the cytosolically exposed domain. Breakdown intermediates, including the lumenal domain of the protein, could be degraded by a different proteolytic system within the ER lumen. A recent paper by Wiertz et al. [8] , which describes the degradation of MHC class I heavy chain in virally-infected cells, has added an interesting new twist to the emerging story.
The human cytomegalovirus (HCMV) compromises the normal cellular response to viral infection by dramatically down-regulating the number of cell-surface MHC class I molecules, which present viral peptides to cytotoxic T cells. This down-regulation is achieved by rapid degradation of newly synthesized MHC class I molecules. The degradation of MHC class I molecules seen in HCMVinfected cells also occurs in cells transfected with a gene from the HCMV unique short region, the US11 gene, which encodes a small type-I transmembrane glycoprotein that resides in the ER. Wiertz et al. [8] demonstrated that, in both types of cell, MHC class I heavy chains disappeared with a half-life of less than one minute.
Treating US11 + cells with brefeldin A, which stops vesicular traffic between the ER and the Golgi complex, had no effect on the half-life of the MHC class I heavy chains [8] . Proteasome inhibitors, however, significantly decreased the rate of MHC class I heavy chain disappearance. Moreover, the rapidly degraded MHC class I molecules had a molecular mass of ~43 kDa and were core glycosylated, whereas proteasome inhibition led to the transient appearance of an ~40 kDa breakdown intermediate that was not glycosylated. There was a precursor-product relationship between the 43 kDa and 40 kDa forms, showing the intermediate form had been deglycosylated; inhibition of Nglycosylation using tunicamycin did not prevent MHC class I heavy chain degradation. Deglycosylation was catalyzed by an N-glycanase-type activity, implying that it may occur in the cytosol. Subcellular fractionation studies were performed by differential centrifugation of control cells and US11 + cells treated with a proteasome inhibitor [8] . In both types of cell, the lumenal ER protein calnexin, the transferrin receptor and MHC class I light chains (␤ 2 -microglobulin) were all quantitatively recovered in the pelleted fractions, as was US11p in the US11 + cells. Core-glycosylated MHC class I heavy chains were also exclusively recovered in the pelleted fractions from control cells. Strikingly, however, the 40 kDa deglycosylated intermediate was present in the supernatant from US11 + cells.
One possible explanation of these observations is that, in US11 + cells, newly synthesized MHC class I heavy chains are somehow dislocated from the ER, exported into the cytosol, deglycosylated and proteolytically degraded. It should be emphasized that the fractionation experiment described above does not prove that the intermediate is in the cytosol. It could, for example, be in small ER-derived vesicles that fail to pellet under the conditions of centrifugation used. What is clear, however, is that the intermediate, in contrast to the normal location of MHC class I heavy chains, appears in a fraction distinct from the bulk of the ER, and that within this alternative location it is susceptible to degradation by the proteasome pathway. Wiertz et al. [8] speculated that dislocation from the ER may have occurred either by the US11 protein somehow interfering with the normal membrane insertion of the MHC class I heavy chain stop-transfer signal, or by preventing the nascent heavy chains from being 'pulled' into the ER lumen by BiP or another ER resident chaperone. In either model, MHC class I heavy chains were envisaged to enter the cytosol by reverse transport through the translocon that normally imports nascent polypeptides into the ER [9] (Fig. 1) . Proteins that fail to fold or assemble into oligomeric structures correctly may be exported back across the ER membrane into the cytosol, where they are degraded by proteasomes. Alternatively, proteasomes may degrade only the cytosolic domain of ER membrane proteins. Lumenal proteins and the lumenal domain of membrane proteins may be degraded by an alternative proteolytic system, perhaps within specialized regions of the ER. If export from the ER to the cytosol occurs, the translocon that imports nascent proteins into the ER (see [9] ) may be used in the reverse direction to export misfolded or unassembled proteins, or a different proteinconducting channel may be used. A number of alternative explanations clearly remain possible. The aberrant proteins could aggregate in specialized regions of the ER, where they might remain membrane associated and attacked at the cytosolic surface by proteasomal proteases. Alternatively, this specialized region of the ER might generate small vesicles containing the proteins that themselves become susceptible to proteasomal attack. Another possibility is that the proteins are degraded while still associated with the ER membrane, perhaps still located in the translocon without requiring reverse transport and release from it. Finally, it is possible that proteins might be exported from the ER via an uncharacterized ER membrane protein transporter, perhaps one dedicated to the export of misfolded or unassembled proteins from the ER for proteolytic degradation in the cytosol. An ER-associated export-degradation pathway may be a feature of all eukaryotic cells as an essential component of the quality control mechanism. The limited data available at present do not, of course, preclude the existence of a proteolytic system within the ER itself.
ER-associated degradation does not appear to be confined to transmembrane proteins. In the absence of light chains, secretory immunoglobulin heavy chains are retained in the ER lumen through binding to the heavy-chain-binding protein BiP, and are eventually degraded. A failure of immunoglobulin M oligomers to polymerize also results in degradation [10] . Retention in the ER lumen per se is not sufficient to promote degradation; several resident ER lumen proteins such as BiP and protein disulphide isomerase are very stable. At present, it is unclear whether secretory proteins subject to ER degradation, such as unassembled immunoglobulins, are degraded within the ER lumen, perhaps in some specialized region, or whether they too are ultimately degraded by proteasomes in the cytosol. If the latter proves to be the case there must be a mechanism for protein export from the ER. Some time ago, the yeast ER was shown to export a glycosylated tripeptide directly into the cytosol, rather than by vesicular transport to the Golgi complex [11] . Although a glycosylated tripeptide clearly falls somewhat short of a typical protein, a more recent report has provided evidence that misfolded prepro-␣ factor in the yeast ER may also be degraded in the cytosol [12] . Significantly, it was noted that mutations in genes encoding a chymotrypsin-like subunit of the yeast proteasome inhibit this degradation [12] .
It seems unlikely that HCMV is the only opportunist to use ER degradation for its own advantage. Other dangerous invaders might parasitize putative ER export machinery. For example, certain cytotoxic proteins such as ricin, which enter mammalian cells by endocytosis, might reach their target substrates in the cytosol by translocating from the ER lumen [13] . If such toxins partially unfold upon reaching the ER lumen, possibly followed by insertion into the ER membrane, they may be exported into the cytosol by a housekeeping system that removes unwanted proteins from this compartment. Should this prove to be the case, the toxins must somehow avoid proteasomal degradation, at least to some extent, to allow refolding into the catalytically-active conformation required to inactivate cellular protein synthesis.
